← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Trial (599)Review article (228)Early study (phase 1 or 2) (41)Case reports (176)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (37)

Filter

Publications and studies (1631)

• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Gamma-Delta T-Cell Lymphoma Following Allogeneic Stem Cell Transplant for Primary Myelofibrosis. (2020/09/07) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one? (2020/09/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. (2020/09/01) ♡
• Mechanoregulation in hematopoiesis and hematologic disorders. (2020/09/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [The prognostic value of ASXL1 mutation in primary myelofibrosis. Literature review and clinical case description]. (2020/09/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study. (2020/08/15) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Platelet-derived growth factor receptor β activation and regulation in murine myelofibrosis. (2020/08/01) ♡
• Neutral effect of Glioma-associated oncogene-1 expression on survival in myelofibrosis. (2020/08/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Diagnosis of pulmonary hypertension by noninvasive methods in hematopoietic cell transplant patients with myelofibrosis. (2020/08/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A Patient With Human Herpesvirus 8-Positive Multicentric Castleman's Disease Who Met Criteria for TAFRO Syndrome: Controversy in Practice? (2020/08/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Extramedullary hematopoiesis causing spinal cord compression with excellent durable response after radiation therapy: Case report and review of the literature. (2020/07/30) ♡
• Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms. (2020/07/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Fibrosis, Thrombosis, and Dacrocytosis: An Unusual Case of Male Systemic Lupus Erythematosus. (2020/07/01) ♡
• Ruxolitinib Discontinuation Syndrome in a Patient With Myelofibrosis to Acute Myeloid Leukemia Transformation. (2020/07/01) ♡
• Examining the Frequency of the JAK2 (V617F) Mutation in Patients with Myeloproliferative Diseases in North Eastern Iran and the Effect of Treatment Intervention. (2020/07/01) ♡
• IL6 inhibition of inflammatory S100A8/9 proteins is NF-κB mediated in essential thrombocythemia. (2020/06/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Strain-resolved microbiome sequencing reveals mobile elements that drive bacterial competition on a clinical timescale. (2020/05/29) ♡
• Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. (2020/05/01) ♡
• Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis. (2020/05/01) ♡
• Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. (2020/05/01) ♡
• Fedratinib in myelofibrosis. (2020/04/28) ♡
• Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms. (2020/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents. (2020/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Myeloproliferative and lymphoproliferative disorders: State of the art. (2020/04/01) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people. (2020/04/01) ♡
• Higher Level of Peripheral Blood CD34 Positive Cells Presented with Unfavorable Prognosis in Intermediate-Low Risk Acute Promyelocytic Leukemia. (2020/04/01) ♡
• Paratrabecular myelofibrosis and occult mastocytosis are strong morphological clues to suspect FIP1L1-PDGFRA translocation in hypereosinophilia. (2020/04/01) ♡
• Systemic Mastocytosis with Associated Primary Myelofibrosis. (2020/04/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. (2020/03/15) ♡
• Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing. (2020/03/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. (2020/03/01) ♡
• Sequential mutational evaluation of CALR-mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression. (2020/03/01) ♡
• Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. (2020/03/01) ♡
• Higher AURKA and PLK1 expression are associated with inferior overall survival in patients with myelofibrosis. (2020/03/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Hydroxyurea-induced Tooth Discoloration. (2020/02/20) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mutational profiling in myelofibrosis: implications for management. (2020/02/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Iatrogenic Kaposi sarcoma in a patient treated with ruxolitinib: A case report. (2020/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The role of calreticulin mutations in myeloproliferative neoplasms. (2020/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. (2020/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Current and future role of fedratinib in the treatment of myelofibrosis. (2020/02/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. (2020/01/01) ♡
• Second Chances. (2020/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance Review. (2020/01/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Myelofibrosis: best practices, controversies and 2019 update. (2020/01/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Pharmacokinetics of Basiliximab for the Prevention of Graft-versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal-Intensity Cyclophosphamide and Fludarabine. (2020/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Novel targets to cure primary myelofibrosis from studies on Gata1(low) mice. (2020/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Recent insights regarding the molecular basis of myeloproliferative neoplasms. (2020/01/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF). (2020/01/01) ♡
• Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. (2020/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Autoimmune myelofibrosis associated with systemic lupus erythematosus: a case report. (2020/01/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.